Accès gratuit
Numéro
Med Sci (Paris)
Volume 29, Numéro 11, Novembre 2013
Page(s) 998 - 1003
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20132911016
Publié en ligne 20 novembre 2013
  1. Muhlberger N, Schwarzer R, Lettmeier B, et al. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health 2009 ; 9 : 34. [CrossRef] [PubMed]
  2. Omland LH, Krarup H, Jepsen P, et al. Mortality in patients with chronic and cleared hepatitis C viral infection: a nationwide cohort study. J Hepatol 2010 ; 53 : 36–42. [CrossRef] [PubMed]
  3. Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 2008 ; 48 : 148–162. [CrossRef] [PubMed]
  4. European association for the study of the liver. EASL clinical practice guidelines: management of chronic hepatitis C virus infection. J Hepatol 2011 ; 55 : 245–64. [CrossRef] [PubMed]
  5. Hermine O, Lefrère F, Bronowicki JP, et al. Regression of splenic lymphoma with lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002 ; 347 : 89–94. [CrossRef] [PubMed]
  6. Fontaine H, Chaix ML, Lagneau JL, et al. Recovery from chronic hepatitis C in long-term responders to ribavirin plus interferon alfa. Lancet 2000 ; 356 : 41. [CrossRef] [PubMed]
  7. Mchutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatement of hepatitis C infection. N Engl J Med 2009 ; 361 : 580–593. [CrossRef] [PubMed]
  8. Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007 ; 147 : 677–684. [CrossRef] [PubMed]
  9. Mallet V, Gilgenkrantz H, Serpaggi J, et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008 ; 149 : 399–403. [CrossRef] [PubMed]
  10. Lee MH, Yang HI, Lu SN, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 2012 ; 206 : 469–477. [CrossRef] [PubMed]
  11. Berenguer J, Rodríguez E, Miralles P, et al. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis 2012 ; 55 : 728–736. [CrossRef] [PubMed]
  12. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007 ; 5 : 453–463. [CrossRef] [PubMed]
  13. Buhler S, Bartenschlager R. New targets for antiviral therapy of chronic hepatitis C. Liver Int 2012 ; 32 : 19–16. [CrossRef]
  14. Yang PL, Gao M, Lin K, et al. Anti-HCV drugs in the pipeline. Curr Opin Virol 2011 ; 1 : 607–616. [CrossRef] [PubMed]
  15. Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009 ; 360 : 1839–1850. [CrossRef] [PubMed]
  16. Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naïve patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentric phase 2 trial. Lancet 2011 ; 376 : 705–716. [CrossRef]
  17. McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010 ; 362 : 1292–1303. [CrossRef] [PubMed]
  18. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011 ; 364 : 2417–2428. [CrossRef] [PubMed]
  19. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011 ; 364 : 1207–1217. [CrossRef] [PubMed]
  20. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011 ; 364 : 2405–2416. [CrossRef] [PubMed]
  21. Cacoub P, Bourlière M, Lübbe J, et al. Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals. J Hepatol 2012 ; 56 : 455–463. [CrossRef] [PubMed]
  22. Hezode C, Dorival C, Zoulim F, et al. Safety of telaprevir or boceprevir in combination with peginterferonalfa/ribavirin, in cirrhotic non responders. First results of the French early access program (ANRS C020-CUPIC). 47th Meeting of the European association for the study of the liver. Barcelona: EASL, 2012 (abstract 8).
  23. Kowdley KV, Lawitz E, Crespo I, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype 1, infection (ATOMIC): an open-label, randomised, multicentre, phase 2 trial. Lancet 2013 ; 381 : 2100–2107. [CrossRef] [PubMed]
  24. Gane EJ, Roberts SK, Stedman CA, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and Danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010 ; 376 : 1467–1475. [CrossRef] [PubMed]
  25. Pol S, Ghalib RH, Rustgi VK, et al. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. Lancet Infect Dis 2012 ; 12 : 671–677. [CrossRef] [PubMed]
  26. Zeuzem S, Asselah T, Angus PW, et al. Efficacy of the protease inhibitor BI 201335, the polymerase inhibitor BI 207127 and ribavirin in patients with chronic hepatitis C. Gastroenterology 2011 ; 141 : 2047–2055. [CrossRef] [PubMed]
  27. Lenz O, Vijgen L, Berke JM, et al. Virologic response and characterisation of HCV genotype 2–6 in patients receiving TMC435 monotherapy (study TMC435–C202). J Hepatol 2013 ; 58 : 445–451. [CrossRef] [PubMed]
  28. Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012 ; 366 : 216–224. [CrossRef] [PubMed]
  29. Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor Sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013 ; 368 : 34–44. [CrossRef] [PubMed]
  30. Poordard F, Lawitz E, Kowdley KV, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 2013 ; 56 : S560.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.